Please Wait.....
Report
Biosimilars: Global Markets
Market Research Report I 2025-03-18 I 219 Pages I BCC Research
Description
Report Scope
This report provides the current and future market potential of biosimilars, with market projections through 2029; and it includes a detailed analysis of the drivers, restraints and opportunities in the biosimilars market. The report also covers the competitive environment of the biosimilars industry and features a product analysis.
For this analysis, the market for biosimilars is segmented based on product type, therapeutic application and region. Based on product type, it is segmented into monoclonal antibodies, recombinant growth factors, recombinant hormones, fusion protein and others (such as LMWHs and interferons). Based on therapeutic application, the market is segmented into the following: cancer and related disorders, autoimmune and inflammatory diseases, diabetes, anemia, growth hormone deficiency and other diseases. Based on geographical region, the biosimilars market is segmented into the following: North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. For market estimate data, 2021 and 2022 serve as the historical years, 2023 as the base year, and 2029 as the forecast year.
The report provides company profiles of key players in the biosimilars market that feature detailed information about each organization's business segments, financials, product portfolios and recent developments.
Report Includes
- 142 data tables and 74 additional tables
- An analysis of the global market trends for biosimilars, with historic revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue growth prospects, along with a market share analysis by product type and sub-type, therapeutic application, and region
- Facts and figures pertaining to the market dynamics, advances in existing biosimilars, regulations and the impact of macroeconomic factors
- Review of the industry structure, emerging trends and developments, clinical trials and approvals, and new product
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- An analysis of key patent publications, grants and applications in biosimilars
- Analysis of the competitive landscape featuring companies' market shares, strategic alliances, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies
- Profiles of the market leaders, including Amgen Inc., Sandoz Group AG, Biocon Biologics Ltd., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Executive Summary
Summary:
The global biosimilars market was valued at $23.8 billion in 2023. The market is expected to grow from $28.5 billion in 2024 to $69.2 billion by 2029, at a compound annual growth rate (CAGR) of 19.4% from 2024 through 2029.
In 2023, the global market for biosimilars was valued at $23.8 billion. This market is forecast to grow at a compound annual growth rate (CAGR) of 19.4% to reach $69.2 billion at the end of 2029.
The two major factors driving the growth of this market are patent expirations of major biologics and the cost-effectiveness and healthcare savings associated with using biosimilars. In the meantime, the factors restraining growth are intellectual property issues, legal issues and manufacturing and supply chain complexities.
The largest share in terms of product type of the global biosimilars market in 2023 was held by monoclonal antibodies; this is expected to grow at a CAGR of 19.8% during the forecast period.
In terms of therapeutic application, the autoimmune and inflammatory diseases segment is forecasted to grow at the fastest CAGR of 20.1% throughout the forecast period. However, the cancer and related disorders segment held for the largest share of 34.2% of the global biosimilars market in 2023, and it is expected to reach a value of $24 billion by 2029.
In terms of region, Europe held the largest market share of 45.8% in 2023. Early adoption and supportive regulatory frameworks, as well as high market penetration coupled with government policies and incentives, are responsible for the European region's large share.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Insights
Chapter 2 Market Overview
Introduction
Terminology of Biosimilars
Key Terms in Biosimilars
WHO Guidelines on Evaluation of Biosimilars
Pharmacovigilance/Post-Approval Monitoring
Biosimilars Vs. Biobetters
Popular Types of Biosimilars
Recombinant Hormones
Recombinant Growth Factors
Monoclonal Antibodies (mAbs)
Fusion Proteins
Interferons
Low Molecular Weight Heparins (LMWHs)
Chapter 3 Market Dynamics
Introduction
Market Drivers
Patent Expirations of Major Biologics
Cost-effectiveness and Healthcare Savings
Market Restraints
Intellectual Property and Legal Issues
Manufacturing and Supply Chain Complexities
Market Opportunities
Increasing Access, Adoption and Awareness
Emerging Markets
Chapter 4 Emerging Technologies
Advanced Analytical Techniques
Single-use Bioreactors
Cell Line Engineering and Expression Systems
Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Global Biosimilars Market, by Product Type
Monoclonal Antibodies
Recombinant Growth Factors
Recombinant Hormones
Fusion Protein
Others
Global Biosimilars Market, by Therapeutic Application
Cancer and Related Disorders
Autoimmune and Inflammatory Diseases
Diabetes
Anemia
Growth Hormone Deficiency
Other Diseases
Geographic Breakdown
Global Biosimilars Market, by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World (RoW)
Chapter 6 Competitive Landscape and Patent Analysis
Overview
Key Market Leaders
Emerging Players
Strategic Analysis
Challenges and Future Trends
Patent Analysis
Patent Regulations in Favor of Branded Biologics
Market Exclusivity
Chapter 7 Regulatory Aspects
Overview
Biosimilar Regulations in Europe
Biosimilar Regulations in the U.S.
Principle of Exclusivity
Biosimilar Regulations in China
Chapter 8 Sustainability in the Global Biosimilars Market: An ESG Perspective
Introduction to ESG
ESG Performance in the Market
ESG Practices in the Biosimilars Industry
Environmental Performance
Concluding Remarks from BCC Research
Chapter 9 Appendix
Research Methodology
Sources
Abbreviations
Company Profiles
ACCORD BIOPHARMA INC.
ALVOTECH
AMGEN INC.
AMNEAL PHARMACEUTICALS LLC.
BIOCON BIOLOGICS LTD.
BIOGEN
CELLTRION INC.
COHERUS BIOSCIENCES
FRESENIUS KABI AG
LILLY
PFIZER INC.
SAMSUNG BIOEPIS
SANDOZ GROUP AG
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.
List of Tables
Summary Table : Global Biosimilars Market, by Region, Through 2029
Table 1 : Differences Between Generic and Biosimilar Drugs
Table 2 : Terminology Related to Biosimilars
Table 3 : Biosimilars Vs. Biobetters
Table 4 : Examples of Approved Biobetters
Table 5 : Representative Biobetters in Clinical Trials
Table 6 : Key Developments in Biosimilar Recombinant Hormones
Table 7 : Key Developments in Biosimilar Recombinant Growth Factors
Table 8 : Key Developments in Biosimilar Monoclonal Antibodies
Table 9 : Key Developments in Enbrel (Etanercept) Biosimilars
Table 10 : Key Developments in Biosimilar Interferons
Table 11 : Key Developments in LMWHs Biosimilars
Table 12 : Global Biosimilars Market, by Product Type, Through 2029
Table 13 : EMA Approved Biosimilar Monoclonal Antibodies
Table 14 : FDA Approved Biosimilar Monoclonal Antibodies
Table 15 : Global Biosimilar Monoclonal Antibodies Market, by Region, Through 2029
Table 16 : Global Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 17 : Global Trastuzumab Biosimilars Market, by Region, Through 2029
Table 18 : Global Rituximab Biosimilars Market, by Region, Through 2029
Table 19 : Global Adalimumab Biosimilars Market, by Region, Through 2029
Table 20 : Global Bevacizumab Biosimilars Market, by Region, Through 2029
Table 21 : Global Infliximab Biosimilars Market, by Region, Through 2029
Table 22 : EMA Approved Recombinant Growth Factors Biosimilars
Table 23 : FDA Approved Recombinant Growth Factors Biosimilars
Table 24 : Global Recombinant Growth Factors Biosimilars Market, by Region, Through 2029
Table 25 : Global Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 26 : Global Filgrastim Biosimilars Market, by Region, Through 2029
Table 27 : Global Epoetin Alfa Biosimilars Market, by Region, Through 2029
Table 28 : Global Pegfilgrastim Biosimilars Market, by Region, Through 2029
Table 29 : EMA Approved Recombinant Hormones Biosimilars
Table 30 : FDA Approved Recombinant Hormones Biosimilars
Table 31 : Global Recombinant Hormones Biosimilars Market, by Region, Through 2029
Table 32 : Global Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 33 : Global Insulin Biosimilars Market, by Region, Through 2029
Table 34 : Global Somatotropin Biosimilars Market, by Region, Through 2029
Table 35 : Global Teriparatide Biosimilars Market, by Region, Through 2029
Table 36 : Global Follitropin Alfa Biosimilars Market, by Region, Through 2029
Table 37 : Global Fusion Protein Biosimilars Market, by Region, Through 2029
Table 38 : Global Other Biosimilars Market, by Region, Through 2029
Table 39 : Global Biosimilars Market, by Therapeutic Application, Through 2029
Table 40 : Global Cancer and Related Disorders Market in Biosimilars, by Region, Through 2029
Table 41 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, by Region, Through 2029
Table 42 : Global Diabetes Market in Biosimilars, by Region, Through 2029
Table 43 : Global Anemia Market in Biosimilars, by Region, Through 2029
Table 44 : Global Growth Hormone Deficiency Market in Biosimilars, by Region, Through 2029
Table 45 : Global Other Diseases Market in Biosimilars, by Region, Through 2029
Table 46 : Global Biosimilars Market, by Region, Through 2029
Table 47 : North American Biosimilars Market, by Country, Through 2029
Table 48 : North American Biosimilars Market, by Product Type, Through 2029
Table 49 : North American Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 50 : North American Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 51 : North American Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 52 : North American Biosimilars Market, by Therapeutic Application, Through 2029
Table 53 : Biosimilar Approvals in the U.S.
Table 54 : U.S. Biosimilars Market, by Product Type, Through 2029
Table 55 : U.S. Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 56 : U.S. Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 57 : U.S. Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 58 : U.S. Biosimilars Market, by Therapeutic Application, Through 2029
Table 59 : Canadian Biosimilars Market, by Product Type, Through 2029
Table 60 : Canadian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 61 : Canadian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 62 : Canadian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 63 : Canadian Biosimilars Market, by Therapeutic Application, Through 2029
Table 64 : Mexican Biosimilars Market, by Product Type, Through 2029
Table 65 : Mexican Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 66 : Mexican Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 67 : Mexican Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 68 : Mexican Biosimilars Market, by Therapeutic Application, Through 2029
Table 69 : Biosimilar Approvals in Europe
Table 70 : European Biosimilars Market, by Country, Through 2029
Table 71 : European Biosimilars Market, by Product Type, Through 2029
Table 72 : European Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 73 : European Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 74 : European Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 75 : European Biosimilars Market, by Therapeutic Application, Through 2029
Table 76 : German Biosimilars Market, by Product Type, Through 2029
Table 77 : German Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 78 : German Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 79 : German Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 80 : German Biosimilars Market, by Therapeutic Application, Through 2029
Table 81 : U.K. Biosimilars Market, by Product Type, Through 2029
Table 82 : U.K. Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 83 : U.K. Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 84 : U.K. Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 85 : U.K. Biosimilars Market, by Therapeutic Application, Through 2029
Table 86 : French Biosimilars Market, by Product Type, Through 2029
Table 87 : French Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 88 : French Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 89 : French Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 90 : French Biosimilars Market, by Therapeutic Application, Through 2029
Table 91 : Italian Biosimilars Market, by Product Type, Through 2029
Table 92 : Italian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 93 : Italian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 94 : Italian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 95 : Italian Biosimilars Market, by Therapeutic Application, Through 2029
Table 96 : Spanish Biosimilars Market, by Product Type, Through 2029
Table 97 : Spanish Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 98 : Spanish Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 99 : Spanish Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 100 : Spanish Biosimilars Market, by Therapeutic Application, Through 2029
Table 101 : Rest of European Biosimilars Market, by Product Type, Through 2029
Table 102 : Rest of European Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 103 : Rest of European Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 104 : Rest of European Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 105 : Rest of European Biosimilars Market, by Therapeutic Application, Through 2029
Table 106 : Asia-Pacific Biosimilars Market, by Country, Through 2029
Table 107 : Asia-Pacific Biosimilars Market, by Product Type, Through 2029
Table 108 : Asia-Pacific Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 109 : Asia-Pacific Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 110 : Asia-Pacific Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 111 : Asia-Pacific Biosimilars Market, by Therapeutic Application, Through 2029
Table 112 : Biosimilar Approvals in China
Table 113 : Chinese Biosimilars Market, by Product Type, Through 2029
Table 114 : Chinese Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 115 : Chinese Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 116 : Chinese Recombinant Hormones Biosimilars, by Product Type, Through 2029
Table 117 : Chinese Biosimilars Market, by Therapeutic Application, Through 2029
Table 118 : Japanese Biosimilars Market, by Product Type, Through 2029
Table 119 : Japanese Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 120 : Japanese Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 121 : Japanese Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 122 : Japanese Biosimilars Market, by Therapeutic Application, Through 2029
Table 123 : Indian Biosimilars Market, by Product Type, Through 2029
Table 124 : Indian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 125 : Indian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 126 : Indian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 127 : Indian Biosimilars Market, by Therapeutic Application, Through 2029
Table 128 : Australian Biosimilars Market, by Product Type, Through 2029
Table 129 : Australian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 130 : Australian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 131 : Australian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 132 : Australian Biosimilars Market, by Therapeutic Application, Through 2029
Table 133 : South Korean Biosimilars Market, by Product Type, Through 2029
Table 134 : South Korean Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 135 : South Korean Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 136 : South Korean Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 137 : South Korean Biosimilars Market, by Therapeutic Application, Through 2029
Table 138 : Rest of Asia-Pacific Biosimilars Market, by Product Type, Through 2029
Table 139 : Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 140 : Rest of Asia-Pacific Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 141 : Rest of Asia-Pacific Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 142 : Rest of Asia-Pacific Biosimilars Market, by Therapeutic Application, Through 2029
Table 143 : RoW Biosimilars Market, by Product Type, Through 2029
Table 144 : RoW Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029
Table 145 : RoW Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029
Table 146 : RoW Recombinant Hormones Biosimilars Market, by Product Type, Through 2029
Table 147 : RoW Biosimilars Market, by Therapeutic Application, Through 2029
Table 148 : Select Strategic Alliances in the Biosimilars Industry, 2022-2024
Table 149 : Leading Biosimilars Companies, by Revenue, 2023
Table 150 : U.S. Patent Expirations and Biosimilars, 2024
Table 151 : Pending Biosimilar Patent Litigation, 2024
Table 152 : FDA Guidelines on Biosimilars, February 2021
Table 153 : Biosimilar Products Approved in China, 2024
Table 154 : Key Focus Areas in ESG Metrics
Table 155 : ESG Rankings for Key Players in Biosimilars Market, 2024*
Table 156 : Information Sources in This Report
Table 157 : Glossary of Terms Used in the Biosimilars Market
Table 158 : Accord BioPharma Inc.: Company Snapshot
Table 159 : Accord BioPharma Inc.: Product Portfolio
Table 160 : Accord BioPharma Inc.: News/Key Developments, 2024
Table 161 : Alvotech: Company Snapshot
Table 162 : Alvotech: Financial Performance, FY 2022 and 2023
Table 163 : Alvotech: Product Portfolio
Table 164 : Alvotech: News/Key Developments, 2024
Table 165 : Amgen Inc.: Company Snapshot
Table 166 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 167 : Amgen Inc.: Product Portfolio
Table 168 : Amgen Inc.: News/Key Developments, 2022-2023
Table 169 : Amneal Pharmaceuticals LLC.: Company Snapshot
Table 170 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2022 and 2023
Table 171 : Amneal Pharmaceuticals LLC.: Product Portfolio
Table 172 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2023-2024
Table 173 : Biocon Biologics Ltd.: Company Snapshot
Table 174 : Biocon Biologics Ltd.: Financial Performance, FY 2022 and 2023
Table 175 : Biocon Biologics Ltd.: Product Portfolio
Table 176 : Biocon Biologics Ltd.: News/Key Developments, 2022-2024
Table 177 : Biogen: Company Snapshot
Table 178 : Biogen: Financial Performance, FY 2022 and 2023
Table 179 : Biogen: Product Portfolio
Table 180 : Biogen: News/Key Developments, 2023-2024
Table 181 : Celltrion Inc.: Company Snapshot
Table 182 : Celltrion Inc.: Financial Performance, FY 2022 and 2023
Table 183 : Celltrion Inc.: Product Portfolio
Table 184 : Celltrion Inc.: News/Key Developments, 2023-2024
Table 185 : Coherus BioSciences: Company Snapshot
Table 186 : Coherus BioSciences: Financial Performance, FY 2022 and 2023
Table 187 : Coherus BioSciences: Product Portfolio
Table 188 : Coherus BioSciences: News/Key Developments, 2024
Table 189 : Fresenius Kabi AG: Company Snapshot
Table 190 : Fresenius Kabi AG: Financial Performance, FY 2022 and 2023
Table 191 : Fresenius Kabi AG: Product Portfolio
Table 192 : Fresenius Kabi AG: News/Key Developments, 2024
Table 193 : Lilly: Company Snapshot
Table 194 : Lilly: Financial Performance, FY 2022 and 2023
Table 195 : Lilly: Product Portfolio
Table 196 : Lilly: News/Key Developments, 2022-2023
Table 197 : Pfizer Inc.: Company Snapshot
Table 198 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 199 : Pfizer Inc.: Product Portfolio
Table 200 : Pfizer Inc.: News/Key Developments, 2023
Table 201 : Samsung Bioepis: Company Snapshot
Table 202 : Samsung Bioepis: Product Portfolio
Table 203 : Samsung Bioepis: News/Key Developments, 2023-2024
Table 204 : Sandoz Group AG: Company Snapshot
Table 205 : Sandoz Group AG: Financial Performance, FY 2022 and 2023
Table 206 : Sandoz Group AG: Product Portfolio
Table 207 : Sandoz Group AG: News/Key Developments, 2024
Table 208 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 209 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
Table 210 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 211 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2023-2024
Table 212 : Viatris Inc.: Company Snapshot
Table 213 : Viatris Inc.: Financial Performance, FY 2022 and 2023
Table 214 : Viatris Inc.: Product Portfolio
Table 215 : Viatris Inc.: News/Key Developments, 2022
List of Figures
Summary Figure : Share of Global Market for Biosimilars, by Region, 2023
Figure 1 : Snapshot of the Market Dynamics for Biosimilars
Figure 2 : Share of Global Market for Biosimilars, by Product Type, 2023
Figure 3 : Global Biosimilar Monoclonal Antibodies Market, by Region, 2021-2029
Figure 4 : Global Recombinant Growth Factors Biosimilars Market, by Region, 2021-2029
Figure 5 : Global Recombinant Hormones Biosimilars Market, by Region, 2021-2029
Figure 6 : Global Fusion Protein Biosimilars Market, by Region, 2021-2029
Figure 7 : Global Other Biosimilars Market, by Region, 2021-2029
Figure 8 : Share of Global Market for Biosimilars, by Therapeutic Application, 2023
Figure 9 : Global Cancer and Related Disorders Market in Biosimilars, 2021-2029
Figure 10 : Global Cancer and Related Disorders Market in Biosimilars, by Region, 2021-2029
Figure 11 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, 2021-2029
Figure 12 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, by Region, 2021-2029
Figure 13 : Global Diabetes Market in Biosimilars, 2021-2029
Figure 14 : Global Diabetes Market in Biosimilars, by Region, 2021-2029
Figure 15 : Global Anemia Market in Biosimilars, 2021-2029
Figure 16 : Global Anemia Market in Biosimilars, by Region, 2021-2029
Figure 17 : Global Growth Hormone Deficiency Market in Biosimilars, 2021-2029
Figure 18 : Global Growth Hormone Deficiency Market in Biosimilars, by Region, 2021-2029
Figure 19 : Global Other Diseases Market in Biosimilars, 2021-2029
Figure 20 : Global Other Diseases Market in Biosimilars, by Region, 2021-2029
Figure 21 : Share of Global Market for Biosimilars, by Region, 2023
Figure 22 : Global Biosimilars Market, by Region, 2021-2029
Figure 23 : Share of North American Market for Biosimilars, by Country, 2023
Figure 24 : U.S. Biosimilars Market, 2021-2029
Figure 25 : Canadian Biosimilars Market, 2021-2029
Figure 26 : Mexican Biosimilars Market, 2021-2029
Figure 27 : Share of European Market for Biosimilars, by Country, 2023
Figure 28 : German Biosimilars Market, 2021-2029
Figure 29 : U.K. Biosimilars Market, 2021-2029
Figure 30 : French Biosimilars Market, 2021-2029
Figure 31 : Italian Biosimilars Market, 2021-2029
Figure 32 : Spanish Biosimilars Market, 2021-2029
Figure 33 : Rest of European Biosimilars Market, 2021-2029
Figure 34 : Share of Asia-Pacific Market for Biosimilars, by Country, 2023
Figure 35 : Chinese Biosimilars Market, 2021-2029
Figure 36 : Japanese Biosimilars Market, 2021-2029
Figure 37 : Indian Biosimilars Market, 2021-2029
Figure 38 : Australian Biosimilars Market, 2021-2029
Figure 39 : South Korean Biosimilars Market, 2021-2029
Figure 40 : Rest of Asia-Pacific Biosimilars Market, 2021-2029
Figure 41 : Snapshot of the ESG Pillars
Figure 42 : Advantages of ESG for Biosimilar Companies
Figure 43 : Share of Biotech Companies Providing ESG Disclosure, 2022
Figure 44 : Share of ESG Disclosure, by Location, 2022
Figure 45 : Alvotech: Revenue Share, by Country/Region, FY 2023
Figure 46 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 47 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2023
Figure 48 : Biocon Biologics Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 49 : Biocon Biologics Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 50 : Biogen: Revenue Share, by Business Unit, FY 2023
Figure 51 : Biogen: Revenue Share, by Country/Region, FY 2023
Figure 52 : Fresenius Kabi AG: Revenue Share, by Business Unit, FY 2023
Figure 53 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 54 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 55 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 56 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 57 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2023
Figure 58 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2023
Figure 59 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 60 : Viatris Inc.: Revenue Share, by Business Unit, FY 2023
Figure 61 : Viatris Inc.: Revenue Share, by Country/Region, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security